Functional (Non Ulcer) Dyspepsia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Functional (Non Ulcer) Dyspepsia – Drugs In Development, 2024 report and make more profitable business decisions.
Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called functional dyspepsia or non-ulcer stomach pain. Signs and symptoms include a burning sensation or discomfort in the upper abdomen or lower chest, sometimes relieved by food or antacids; bloating; belching; and nausea. The predisposing factors include excessive consumption of caffeine or alcohol, smoking, and taking certain medications, especially certain over-the-counter pain relievers such as aspirin and ibuprofen (advil, motrin, others), which can cause stomach problems. Treatment includes medications to reduce acid production, antibiotics, and low-dose antidepressants.
The Functional (Non Ulcer) Dyspepsia drugs in development market research report provide comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Functional (Non Ulcer) Dyspepsia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Functional (Non Ulcer) Dyspepsia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Functional (Non Ulcer) Dyspepsia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Functional (Non Ulcer) Dyspepsia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Dong-A ST Co LtdFaes Farma SA
ISOThrive Inc
Kyungpook National University
Meiji Seika Pharma Co Ltd
Mitsubishi Tanabe Pharma Corp
RaQualia Pharma Inc
Renexxion LLC
Sebela Pharmaceuticals Inc
Sinovant Sciences HK Ltd
Technical University of Munich
Vanda Pharmaceuticals Inc
Zeria Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Functional (Non Ulcer) Dyspepsia reports